{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:55:48Z","timestamp":1762509348195,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>An important number of breast and ovarian cancer cases is due to a strong genetic predisposition. The main tool for identifying individuals at risk is recognizing a suggestive family history of cancer. We present a prospective study on applying three selected clinical guidelines to a cohort of 1000 Slovenian women to determine the prevalence of at-risk women according to each of the guidelines and analyze the differences amongst the guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Personal and family history of cancer was collected for 1000 Slovenian women. Guidelines by three organizations: National Comprehensive Cancer Network (NCCN), American College of Medical Genetics in cooperation with National Society of Genetic Counselors (ACMG\/NSGC), and Society of Gynecologic Oncology (SGO) were applied to the cohort. The number of women identified, the characteristics of the high-risk population, and the agreement between the guidelines were explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NCCN guidelines identify 13.2% of women, ACMG\/NSGC guidelines identify 7.1% of women, and SGO guidelines identify 7.0% of women from the Slovenian population, while 6.2% of women are identified by all three guidelines as having high-risk for hereditary breast and ovarian cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We identified 13.7% of women from the Slovenian population as being at an increased risk for breast and ovarian cancer based on their personal and family history of cancer using all of the guidelines. There are important differences between the guidelines. NCCN guidelines are the most inclusive, identifying nearly twice the amount of women as high-risk for hereditary breast and ovarian cancer as compared to the AGMG\/NSCG and SGO guidelines in the Slovenian population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08400-8","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T12:04:21Z","timestamp":1622721861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7528-3987","authenticated-orcid":false,"given":"Urska","family":"Kotnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borut","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Lovrecic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"1-2","key":"8400_CR1","first-page":"43","volume":"35","author":"J Kirk","year":"2006","unstructured":"Kirk J, Brennan M, Houssami N, Ung O. An approach to the patient with a family history of breast cancer. Aust Fam Physician. 2006;35(1-2):43\u20137.","journal-title":"Aust Fam Physician"},{"issue":"1","key":"8400_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1524-4741.2003.09105.x","volume":"9","author":"KS Hughes","year":"2003","unstructured":"Hughes KS, Roche C, Campbell CT, Siegel N, Salisbury L, Chekos A, et al. Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. Breast J. 2003;9(1):19\u201325. https:\/\/doi.org\/10.1046\/j.1524-4741.2003.09105.x.","journal-title":"Breast J"},{"key":"8400_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmg.40.7.e83","volume":"40","author":"CE Jacobi","year":"2003","unstructured":"Jacobi CE, Jonker MA, Nagelkerke NJ, van Houwelingen JC, de Bock GH. Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care. J Med Genet. 2003;40:1\u20134.","journal-title":"J Med Genet"},{"issue":"7-8","key":"8400_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000294469","volume":"13","author":"PL Mai","year":"2010","unstructured":"Mai PL, Wideroff L, Greene MH, Graubard BI. Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study. Public Health Genomics. 2010;13(7-8):495\u2013503. https:\/\/doi.org\/10.1159\/000294469.","journal-title":"Public Health Genomics"},{"issue":"3","key":"8400_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijgo.2013.12.001","volume":"124","author":"D Mutch","year":"2014","unstructured":"Mutch D, Denny L, Quinn M. Hereditary gynecologic cancers. Int J Gynecol Obstet. 2014;124(3):189\u201392. https:\/\/doi.org\/10.1016\/j.ijgo.2013.12.001.","journal-title":"Int J Gynecol Obstet"},{"issue":"7","key":"8400_CR6","first-page":"491","volume":"16","author":"NH Sulai","year":"2018","unstructured":"Sulai NH, Tan AR. Development of poly (ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer. Clin Adv Hematol Oncol. 2018;16(7):491\u2013501.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"34","key":"8400_CR7","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","volume":"35","author":"CP Childers","year":"2017","unstructured":"Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800\u20136. https:\/\/doi.org\/10.1200\/JCO.2017.73.6314.","journal-title":"J Clin Oncol"},{"key":"8400_CR8","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2147\/CMAR.S189627","volume":"11","author":"C Forbes","year":"2019","unstructured":"Forbes C, Fayter D, De Kock SK, Quek RGW. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019;11:2321\u201337. https:\/\/doi.org\/10.2147\/CMAR.S189627.","journal-title":"Cancer Manag Res"},{"issue":"23","key":"8400_CR9","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1002\/cncr.26166","volume":"117","author":"KF Trivers","year":"2011","unstructured":"Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CHA, Lishner DM, et al. Reported referral for genetic counseling or BRCA 1\/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117(23):5334\u201343. https:\/\/doi.org\/10.1002\/cncr.26166.","journal-title":"Cancer."},{"issue":"6","key":"8400_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3322\/caac.21408","volume":"67","author":"PJ Hoskins","year":"2017","unstructured":"Hoskins PJ, Gotlieb WH. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature. CA Cancer J Clin. 2017;67(6):493\u2013506. https:\/\/doi.org\/10.3322\/caac.21408.","journal-title":"CA Cancer J Clin"},{"key":"8400_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","volume":"83","author":"B Ponder","year":"2000","unstructured":"Ponder B, Pharoah PDP, Ponder BAJ, Lipscombe JM, Basham V, Gregory J, et al. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000;83:1301\u20138.","journal-title":"Br J Cancer"},{"key":"8400_CR12","unstructured":"Daly MB, Pilarski R, Berry MP, Bury SS, Friedman S, Garber E, et al. Genetic\/Familial High-Risk Assessment: Breast and Ovarian, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Accessed 21 May 2019."},{"issue":"19","key":"8400_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"6","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;6(19):77\u2013102.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"8400_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","volume":"17","author":"H Hampel","year":"2015","unstructured":"Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of genetic counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70\u201387. https:\/\/doi.org\/10.1038\/gim.2014.147.","journal-title":"Genet Med"},{"issue":"1","key":"8400_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","volume":"136","author":"JM Lancaster","year":"2015","unstructured":"Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136(1):3\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.009.","journal-title":"Gynecol Oncol"},{"issue":"31","key":"8400_CR16","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","volume":"33","author":"ME Robson","year":"2015","unstructured":"Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33(31):3660\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.63.0996.","journal-title":"J Clin Oncol"},{"issue":"7","key":"8400_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s11606-009-1009-6","volume":"24","author":"DE Levy","year":"2009","unstructured":"Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med. 2009;24(7):822\u20138. https:\/\/doi.org\/10.1007\/s11606-009-1009-6.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"8400_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12325-016-0281-1","volume":"33","author":"DM Eccles","year":"2016","unstructured":"Eccles DM, Balma\u00f1a J, Clune J, Ehlken B, Gohlke A, Hirst C, et al. Selecting patients with ovarian Cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review. Adv Ther. 2016;33(2):129\u201350. https:\/\/doi.org\/10.1007\/s12325-016-0281-1.","journal-title":"Adv Ther"},{"issue":"1","key":"8400_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12885-017-3422-2","volume":"17","author":"EM Grindedal","year":"2017","unstructured":"Grindedal EM, Heramb C, Karsrud I, Ariansen SL, M\u00e6hle L, Undlien DE, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017;17(1):438. https:\/\/doi.org\/10.1186\/s12885-017-3422-2.","journal-title":"BMC Cancer"},{"issue":"1","key":"8400_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ygyno.2015.04.029","volume":"138","author":"T Febbraro","year":"2015","unstructured":"Febbraro T, Robison K, Wilbur JS, Laprise J, Bregar A, Lopes V, et al. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol. 2015;138(1):109\u201314. https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.029.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"8400_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453\u201360. https:\/\/doi.org\/10.1200\/JCO.18.01631.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8400_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.gim.0000204458.84988.f2","volume":"8","author":"GE Palomaki","year":"2006","unstructured":"Palomaki GE, McClain MR, Steinort K, Sifri R, LoPresti L, Haddow JE. Screen-positive rates and agreement among six family history screening protocols for breast\/ovarian cancer in a population-based cohort of 21- to 55-year-old women. Genet Med. 2006;8(3):161\u20138. https:\/\/doi.org\/10.1097\/01.gim.0000204458.84988.f2.","journal-title":"Genet Med"},{"issue":"12","key":"8400_CR23","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1002\/cam4.1210","volume":"6","author":"N Campacci","year":"2017","unstructured":"Campacci N, de Lima JO, Carvalho AL, Michelli RD, Haikel R, Mauad E, et al. Identification of hereditary cancer in the general population: development and validation of a screening questionnaire for obtaining the family history of cancer. Cancer Med. 2017;6(12):3014\u201324. https:\/\/doi.org\/10.1002\/cam4.1210.","journal-title":"Cancer Med"},{"issue":"4","key":"8400_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10689-008-9188-6","volume":"7","author":"MR McClain","year":"2008","unstructured":"McClain MR, Palomaki GE, Hampel H, Westman JA, Haddow JE. Screen positive rates among six family history screening protocols for breast\/ovarian cancer in four cohorts of women. Familial Cancer. 2008;7(4):341\u20135. https:\/\/doi.org\/10.1007\/s10689-008-9188-6.","journal-title":"Familial Cancer"},{"issue":"15","key":"8400_CR25","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1002\/cam4.2534","volume":"8","author":"S Greenberg","year":"2019","unstructured":"Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A, et al. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med. 2019;8(15):6789\u201398. https:\/\/doi.org\/10.1002\/cam4.2534.","journal-title":"Cancer Med"},{"issue":"2","key":"8400_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ygyno.2017.06.002","volume":"146","author":"LM Randall","year":"2017","unstructured":"Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, et al. Multi-disciplinary summit on genetics services for women with gynecologic cancers: a Society of Gynecologic Oncology White Paper. Gynecol Oncol. 2017;146(2):217\u201324. https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.002.","journal-title":"Gynecol Oncol"},{"key":"8400_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22:276\u201382.","journal-title":"Biochem Med"},{"issue":"28","key":"8400_CR28","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33(28):3124\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.59.7401.","journal-title":"J Clin Oncol"},{"key":"8400_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/EDBK_238977","volume":"39","author":"R Pilarski","year":"2019","unstructured":"Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate Cancer families. Am Soc Clin Oncol Educ B. 2019;39:79\u201386.","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"30","key":"8400_CR30","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","volume":"35","author":"K Shindo","year":"2017","unstructured":"Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382\u201390. https:\/\/doi.org\/10.1200\/JCO.2017.72.3502.","journal-title":"J Clin Oncol"},{"key":"8400_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"2","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate Cancer. World J Oncol. 2019;2:63\u201389.","journal-title":"World J Oncol"},{"issue":"11","key":"8400_CR32","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","volume":"23","author":"JB Hjelmborg","year":"2014","unstructured":"Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, et al. The heritability of prostate cancer in the Nordic twin study of Cancer. Cancer Epidemiol Biomark Prev. 2014;23(11):2303\u201310. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0568.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"8","key":"8400_CR33","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/bjc.2011.383","volume":"105","author":"Z Kote-Jarai","year":"2011","unstructured":"Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105(8):1230\u20134. https:\/\/doi.org\/10.1038\/bjc.2011.383.","journal-title":"Br J Cancer"},{"issue":"5","key":"8400_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1603144.","journal-title":"N Engl J Med"},{"issue":"23","key":"8400_CR35","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jnci\/djj465","volume":"98","author":"HA Risch","year":"2006","unstructured":"Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694\u2013706. https:\/\/doi.org\/10.1093\/jnci\/djj465.","journal-title":"J Natl Cancer Inst"},{"issue":"2, Part 1","key":"8400_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","volume":"120","author":"KA Schrader","year":"2012","unstructured":"Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 2012;120(2, Part 1):235\u201340. https:\/\/doi.org\/10.1097\/AOG.0b013e31825f3576.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"8400_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12875-016-0521-0","volume":"17","author":"BL Solomon","year":"2016","unstructured":"Solomon BL, Whitman T, Wood ME. Contribution of extended family history in assessment of risk for breast and colon cancer. BMC Fam Pract. 2016;17(1):126. https:\/\/doi.org\/10.1186\/s12875-016-0521-0.","journal-title":"BMC Fam Pract"},{"issue":"23","key":"8400_CR38","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"JAMA."},{"key":"8400_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/jmg.40.3.e25","volume":"40","author":"MA Jonker","year":"2003","unstructured":"Jonker MA, de Bock GH, Hoogendoorn WE, van Asperen CJ, van Houwelingen JC. Little value from including cousins in individual risk assessment of hereditary breast cancer: a simulation study. J Med Genet. 2003;40:3.","journal-title":"J Med Genet"},{"issue":"34","key":"8400_CR40","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","volume":"34","author":"KN Maxwell","year":"2016","unstructured":"Maxwell KN, Domchek SM, Nathanson KL, Robson ME. Population frequency of germline BRCA1\/2 mutations. J Clin Oncol. 2016;34(34):4183\u20135. https:\/\/doi.org\/10.1200\/JCO.2016.67.0554.","journal-title":"J Clin Oncol"},{"issue":"10","key":"8400_CR41","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","volume":"25","author":"S Yang","year":"2018","unstructured":"Yang S, Axilbund JE, O\u2019Leary E, Michalski ST, Evans R, Lincoln SE, et al. Underdiagnosis of hereditary breast and ovarian Cancer in Medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25(10):2925\u201331. https:\/\/doi.org\/10.1245\/s10434-018-6621-4.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"8400_CR42","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.6004\/jnccn.2018.0083","volume":"16","author":"TB Bevers","year":"2018","unstructured":"Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, et al. Breast Cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(11):1362\u201389. https:\/\/doi.org\/10.6004\/jnccn.2018.0083.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"8400_CR43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ejso.2015.01.021","volume":"41","author":"F Aloraifi","year":"2015","unstructured":"Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O\u2019Doherty A, et al. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer. Eur J Surg Oncol. 2015;41(5):641\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2015.01.021.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"8400_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/sj.bjc.6604830","volume":"100","author":"KA Metcalfe","year":"2009","unstructured":"Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer. 2009;100(2):421\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6604830.","journal-title":"Br J Cancer"},{"issue":"5","key":"8400_CR45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/0284186X.2017.1404635","volume":"57","author":"A Augustinsson","year":"2018","unstructured":"Augustinsson A, Ellberg C, Kristoffersson U, Borg \u00c5, Olsson H. Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer. Acta Oncol (Madr). 2018;57(5):595\u2013603. https:\/\/doi.org\/10.1080\/0284186X.2017.1404635.","journal-title":"Acta Oncol (Madr)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08400-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T12:06:40Z","timestamp":1622722000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08400-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8400"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08400-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"7 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Slovenian National Medical Ethics Committee (0120\u2013113\/2018\/4). All patients gave informed consent for participation in this study per the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"665"}}